A very recent meta-analysis including a total of 1950 patients with type 2 diabetes with and without NAFLD concluded that SGLT-2 inhibitor treatment improved liver structure and function (49). Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.